ReviewThe ocular surface2019
The therapeutic application of mesenchymal stem cells at the ocular surface.
Review in The ocular surface, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Role of stem cells in ocular diseases: Progress and challenges.Journal of biomedical research · 2026Article
- Long-Term Tolerability and Safety of AAV5-Id3 Gene Therapy to Eyes.Translational vision science & technology · 2026Article
- Subconjunctival Injection of Mesenchymal Stem Cells for Corneal Wound Healing After Chemical Injury: Impact on Epithelial Coverage, Limbal Ischemia, and Ocular Surface Inflammatory.Frontiers in medicine · 2026Article
- Tracking adipose-derived mesenchymal stromal cells in the eye: Integrating IVIS imaging and Alu PCR for enhanced detection of human cells.Regenerative therapy · 2025Article
- Review
- Identification of glutamine as a potential therapeutic target in dry eye disease.Signal transduction and targeted therapy · 2025Article
- Combined Therapy Using Mesenchymal Stem Cells and Metal Nanoparticles: Perspectives for Ocular Injuries and Diseases.International journal of nanomedicine · 2025Review
- Molecular Mechanisms Responsible for Mesenchymal Stem Cell-Dependent Attenuation of Tear Hyperosmolarity and Immune Cell-Driven Inflammation in the Eyes of Patients with Dry Eye Disease.Diseases (Basel, Switzerland) · 2024Review
- A novel tissue-engineered corneal epithelium based on ultra-thin amniotic membrane and mesenchymal stem cells.Scientific reports · 2024Article
- Unlocking the versatile potential: Adipose-derived mesenchymal stem cells in ocular surface reconstruction and oculoplastics.World journal of stem cells · 2024Review
- Licensing effects of inflammatory factors and TLR ligands on the regenerative capacity of adipose-derived mesenchymal stem cells.Frontiers in cell and developmental biology · 2024Article
- Corneal fibrosis abrogation by a localized AAV-mediated inhibitor of differentiation 3 (Id3) gene therapy in rabbit eyes in vivo.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- Cotransplantation of Limbal Epithelial and Stromal Cells for Ocular Surface Reconstruction.Ophthalmology science · 2022Article
- Mouse Degenerating Optic Axons Survived by Human Embryonic Stem Cell-Derived Neural Progenitor Cells.Cell journal · 2022Article
- Mesenchymal stromal cells for the treatment of ocular autoimmune diseases.Progress in retinal and eye research · 2021Review
- The Limbal Niche and Regenerative Strategies.Vision (Basel, Switzerland) · 2021Review
- Preclinical Evaluation of the Safety and Efficacy of Cryopreserved Bone Marrow Mesenchymal Stromal Cells for Corneal Repair.Translational vision science & technology · 2021Article
- Review
- The potential of lipid mediator networks as ocular surface therapeutics and biomarkers.The ocular surface · 2021Review
- Animal models of high-risk corneal transplantation: A comprehensive review.Experimental eye research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The therapeutic potential of mesenchymal stem cells (MSCs) has been heralded by their multipotentiality and immunomodulatory capacity. MSCs migrate toward sites of tissue damage, where specific pro-inflammatory factors 'license' their immunosuppressive functions. Recent studies in animal models of ocular surface disease have demonstrated the potential of MSC-derived therapies to limit inflammation and promote tissue repair. Herein, we review the immunoregulatory mechanisms of MSCs, as well as strategies to harness their regenerative function at the cornea. We examine reports of the therapeutic application of MSCs in the setting of ocular surface inflammation; including corneal injury, transplantation, ocular surface autoimmunity and allergy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.